Literature DB >> 23912312

The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population.

Won Jae Yang.   

Abstract

This study aimed to determine if lower serum total prostate-specific antigen (PSA) levels in obese Korean men affect prostate cancer (PCa) screening, as an increased body mass index (BMI) is inversely associated with the PSA level. Between March 2007 and December 2012, 22 208 native Korean men who were eligible to receive a serum PSA test were recruited. Logistic regression was used to estimate the odds of an 'abnormal' PSA (≥2.5 or ≥4.0 ng ml(-1)) in these men (age: 45-75 years, PSA <10 ng ml(-1)) based on BMI, which was categorized as normal (BMI <25 kg m(-2)) and obese (BMI ≥25 kg m(-2)). In all, 20 509 men (92.3%) were included in the study after applying the inclusion criteria. After controlling for age, there was a statistically significant trend towards a lower likelihood of having a serum PSA level ≥2.5 ng ml(-1) with an increased BMI, with obese men having an 18% lower likelihood (odds ratio: 0.823, 95% confidence interval: 0.743-0.912; P<0.001) compared to men with a normal BMI. Obese men were approximately 82% as likely to have a PSA level ≥2.5 ng ml(-1) as men with a normal BMI. These results might affect PCa screening using serum total PSA. Further studies are needed to better define these results in clinical biopsy practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23912312      PMCID: PMC3854050          DOI: 10.1038/aja.2013.77

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  21 in total

Review 1.  Criteria and classification of obesity in Japan and Asia-Oceania.

Authors:  Masao Kanazawa; Nobuo Yoshiike; Toshimasa Osaka; Yoshio Numba; Paul Zimmet; Shuji Inoue
Journal:  World Rev Nutr Diet       Date:  2005       Impact factor: 0.575

2.  Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort.

Authors:  Carmen Rodriguez; Stephen J Freedland; Anusila Deka; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12-19       Impact factor: 4.254

3.  Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States.

Authors:  C Rodriguez; A V Patel; E E Calle; E J Jacobs; A Chao; M J Thun
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-04       Impact factor: 4.254

4.  T1c prostate cancer detection rate and pathologic characteristics: comparison between patients with serum prostate-specific antigen range of 3.0 to 4.0 ng/mL and 4.1 to 10.0 ng/mL in Korean population.

Authors:  Hyoung Keun Park; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  Urology       Date:  2006-06-27       Impact factor: 2.649

5.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

Authors:  W J Catalona; D S Smith; D K Ornstein
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

Review 6.  Future prospects in prostate cancer.

Authors:  N J Hegarty; J M Fitzpatrick; J P Richie; P T Scardino; R W deVere White; F H Schröder; D S Coffey
Journal:  Prostate       Date:  1999-09-01       Impact factor: 4.104

7.  Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.

Authors:  Zhihong Gong; Marian L Neuhouser; Phyllis J Goodman; Demetrius Albanes; Chen Chi; Ann W Hsing; Scott M Lippman; Elizabeth A Platz; Michael N Pollak; Ian M Thompson; Alan R Kristal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

8.  Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.

Authors:  Takashi Kobayashi; Koji Nishizawa; Keiji Ogura; Kenji Mitsumori; Yoshihiro Ide
Journal:  Urology       Date:  2004-04       Impact factor: 2.649

Review 9.  Obesity and prostate cancer: weighing the evidence.

Authors:  Emma H Allott; Elizabeth M Masko; Stephen J Freedland
Journal:  Eur Urol       Date:  2012-11-15       Impact factor: 20.096

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  3 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS.

Authors:  Patrick Temi Adegun; Philip Babatunde Adebayo; Samuel Adeniran Atiba
Journal:  Asian J Urol       Date:  2015-06-24

3.  Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.

Authors:  Sean Harrison; Kate Tilling; Emma L Turner; Richard M Martin; Rosie Lennon; J Athene Lane; Jenny L Donovan; Freddie C Hamdy; David E Neal; J L H Ruud Bosch; Hayley E Jones
Journal:  Cancer Causes Control       Date:  2020-03-11       Impact factor: 2.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.